CeriBell (NASDAQ:CBLL) Shares Down 3.3% - Time to Sell?

Shares of CeriBell (NASDAQ:CBLL - Get Free Report) were down 3.3% during mid-day trading on Friday . The company traded as low as $24.66 and last traded at $25.00. Approximately 24,940 shares traded hands during trading, a decline of 54% from the average daily volume of 54,645 shares. The stock had previously closed at $25.86.

Analysts Set New Price Targets

CBLL has been the topic of a number of analyst reports. Canaccord Genuity Group initiated coverage on CeriBell in a research report on Tuesday, November 5th. They set a "buy" rating and a $30.00 price objective on the stock. Canaccord Genuity Group lifted their price target on shares of CeriBell from $31.00 to $33.00 and gave the company a "buy" rating in a report on Monday, December 9th. TD Cowen increased their price objective on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research note on Monday, December 9th. JPMorgan Chase & Co. started coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an "overweight" rating and a $32.00 price objective on the stock. Finally, William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an "outperform" rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $32.60.

CeriBell Price Performance

The stock's 50-day simple moving average is $27.56.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The company had revenue of $17.20 million for the quarter, compared to the consensus estimate of $17.06 million. Equities analysts predict that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.